Xenon Pharma

XENE

Current ValuationThe current P/E ratio is -8.36, within the reasonable range, cheaper than 30.47% of the time in the past 10 years, and the industry ranks 441/606, the industry Median -1.86.

-8.36xP/E
Stock price$35.34Earnings per share$-4.23

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
021426384

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-59.72x150.60%$193.48B
MRNAUSModerna
-25.35x17.00%$79.89B
CSLLYUSCSL Limited
-25.70x--$66.28B
NTRAUSNatera
-302.72x5.57%$58.23B
RVMDUSRevolution Medicines
-22.67x61.94%$40.08B
ROIVUSRoivant Sciences
-98.99x146.69%$26.36B
BNTXUSBioNTech SE
-11.32x19.30%$22.13B
INSMUSInsmed
-23.30x75.01%$20.39B
BBIOUSBridgebio Pharma
-19.37x27.81%$13.40B
SMMTUSSummit Therapeutics
-14.42x19.79%$12.34B
MDGLUSMadrigal Pharma
-30.86x51.30%$10.03B
PCVXUSVaxcyte
-8.94x47.91%$9.51B
TWSTUSTwist Bioscience
-67.37x28.63%$9.21B
KYMRUSKymera Therapeutics
-30.74x5.24%$9.21B
IBRXUSImmunityBio
-8.78x151.32%$8.71B
CYTKUSCytokinetics
-9.52x6.85%$8.51B
ARWRUSArrowHead Pharma
-25.61x35,923.70%$8.20B
SYREUSSpyre Therapeutics
-53.02x45.60%$7.96B
ABVXUSAbivax SA
-16.50x22.99%$7.67B
IONSUSIonis Pharma
-12.62x49.51%$7.13B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.